Skip to content

Study · In vitro (cells) · 2004

5 results

[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ].

Meskhi T, Khachidze D, Barbakadze Sh, Madzhagaladze G, Gorgoshidze M, Monaselidze D, Lezhava T, Tadumadze N

Biofizika1 Nov 2004

PMID15612551 (opens in a new tab)PepBankPUB-15612551
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human lymphocytes, prostamax redistributed heat among endotherms T(d)III and T(d)IV.

    In plain wordsIn cells, prostamax redistributed heat among two endotherms.

    Peptide
    Prostamax (KEDP)
    Outcome
    Direction not reportedHeat redistribution among endotherms
    Study

    humann: not reported in source

    human lymphocytes in situ
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptide bioregulator prostamax causes a redistribution of heat among endotherms T(d)III and T(d)IV and a shift of both endotherms to low temperatures by 2.9 and 1.0 degrees C, respectively.
  2. 02LabIn vitro (cells)Mechanism

    In human lymphocytes, prostamax shifted the T(d)III endotherm to lower temperatures by 2.9 degrees C.

    In plain wordsIn cells, prostamax lowered the T(d)III endotherm temperature by 2.9 degrees C.

    Peptide
    Prostamax (KEDP)
    Outcome
    DecreaseT(d)III endotherm temperature
    Study

    humann: not reported in source

    human lymphocytes in situ
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Temperature shift
    2.9 degrees C
    T(d)III toward lower temperatures

    Source sentences

    Summary
    The peptide bioregulator prostamax causes a redistribution of heat among endotherms T(d)III and T(d)IV and a shift of both endotherms to low temperatures by 2.9 and 1.0 degrees C, respectively.
  3. 03LabIn vitro (cells)Mechanism

    In human lymphocytes, prostamax shifted the T(d)IV endotherm to lower temperatures by 1.0 degrees C.

    In plain wordsIn cells, prostamax lowered the T(d)IV endotherm temperature by 1.0 degrees C.

    Peptide
    Prostamax (KEDP)
    Outcome
    DecreaseT(d)IV endotherm temperature
    Study

    humann: not reported in source

    human lymphocytes in situ
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Temperature shift
    1 degrees C
    T(d)IV toward lower temperatures

    Source sentences

    Summary
    The peptide bioregulator prostamax causes a redistribution of heat among endotherms T(d)III and T(d)IV and a shift of both endotherms to low temperatures by 2.9 and 1.0 degrees C, respectively.
  4. 04LabIn vitro (cells)Mechanism

    In human lymphocytes, prostamax weakly decreased T(d)VIII compared with untreated cells.

    In plain wordsIn cells, prostamax slightly lowered T(d)VIII compared with untreated cells.

    Peptide
    Prostamax (KEDP)
    Outcome
    DecreaseT(d)VIII
    Study

    humann: not reported in source

    human lymphocytes in situ
    Comparator
    Untreated lymphocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A weak decrease in T(d)VIII and T(d)VII of lymphocytes treated with prostamax compared to untreated ones is connected with small structural changes of nucleosomal organization in the 10-nm filament and 30-nm-thick fiber.
  5. 05LabIn vitro (cells)Mechanism

    In human lymphocytes, prostamax weakly decreased T(d)VII compared with untreated cells.

    In plain wordsIn cells, prostamax slightly lowered T(d)VII compared with untreated cells.

    Peptide
    Prostamax (KEDP)
    Outcome
    DecreaseT(d)VII
    Study

    humann: not reported in source

    human lymphocytes in situ
    Comparator
    Untreated lymphocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A weak decrease in T(d)VIII and T(d)VII of lymphocytes treated with prostamax compared to untreated ones is connected with small structural changes of nucleosomal organization in the 10-nm filament and 30-nm-thick fiber.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.